Listing a study does not mean it has been evaluated by the U. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : November 5, See Contacts and Locations. Study Description.
These samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases.
The investigators will also study the tumor cells at the level of the participant's genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes. Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking procedure, which involves donating bone marrow and blood samples.
These will be collected only at times when necessary clinical bone marrow samples are obtained and will not require an extra visit to the doctor. The investigators are also requesting permission to collect medical information from the participant's record and link this information to the specimens so that we may better understand the participant's response to treatment.
For samples obtained prior to beginning therapy, this information might allow us to develop new ways of predicting response to therapy.
Multiple Myeloma and Related Disorders | SpringerLink
The investigators are also requesting permission to store samples of blood and bone marrow to establish a tissue bank for future research to these diseases. These samples will be de-identified; any of the participant's personal health information identifiers will be removed. The timing of sample collection will coincide with other bone marrow tests required to assess the response to therapy or any other clinical purpose.
FDA Resources. Outcome Measures. To determine whether patients with MM, WM, MGUS, sMM, or related disorders have unique proteomic, genetic and epigenetic characteristics in the malignant clone or the microenvironment and linking information to the clinical characteristics of the patients through exploratory tests.
Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Some conditions may occur in people diagnosed with multiple myeloma.
Plasma cell disorders and myeloma terminology and classifications
Peripheral neuropathy causes weakness, loss of sensation, pins and needles or burning pain in the hands and feet. Organomegaly refers to organ enlargement. The endocrine system is the group of hormone-producing glands and tissues that help regulate growth, sexual development and other body functions. M-proteins are found in the blood and urine. There may also be plasma cell tumours, called plasmacytomas. Skin changes might include skin darkening, thickening or tightening.
- Optical resonators fundamentals, advanced concepts and applications.
- People of MSK.
- MMRF on Twitter!
Other changes that may occur include hair growth on the face, limbs and chest, swelling edema of the legs and feet, and whitening of the nails. Treatment options for osteosclerotic myeloma include: radiation therapy chemotherapy stem cell transplant targeted therapy hormone replacement therapy for those whose endocrine organs are affected.
People with Waldenstrom macroglobulinemia make too much immunoglobulin M IgM. A high amount of IgM in the blood will cause the blood to thicken, leading to a condition called hyperviscosity syndrome. Hyperviscosity causes problems with the circulation of the blood through the body. Signs and symptoms of hyperviscosity syndrome includes headaches and feeling dizzy, weak or tired. Amyloid refers to a protein or part of a protein that forms abnormal clumps in the body.
In light chain amyloidosis, the light chains of an immunoglobulin build up in tissues of the body called amyloid deposits. Amyloid can build up in any tissue and interfere with its function. It may also be associated with other B-cell cancers, such as lymphoma and chronic lymphocytic leukemia CLL.
Amyloid is sometimes seen on a bone marrow biopsy sample, but a doctor may need to biopsy other tissues, such as the fat on the abdomen belly , to look for amyloid. In rare cases, a doctor will biopsy the heart or kidneys to look for amyloid if a person is having heart or kidney problems. Treatment for amyloidosis is similar to treatment for multiple myeloma.
It targets the abnormal plasma cells. Treatment options include: chemotherapy radiation therapy stem cell transplant. Plasma cell leukemia PCL is a rare, aggressive condition where large numbers of plasma cells circulate in the blood. The circulating plasma cells may be the first evidence of disease called primary PCL or may develop in the later stages of multiple myeloma called secondary PCL. PCL is more aggressive than multiple myeloma.
Heavy chain disease is a rare disease of B cells also called B lymphocytes. In heavy chain disease, plasma cells make incomplete immunoglobulin molecules that only have the heavy chain part of the immunoglobulin. There are 3 types of heavy chain disease, which are classified according to the type of heavy chain.
Multiple Myeloma and Related Disorders
Find out more about immunoglobulins. Heavy chains of IgA are found in IgA heavy chain disease also called alpha heavy chain disease. IgA is the most common type of heavy chain disease, and it affects the gastrointestinal tract. Experts believe it is caused by long-term stimulation of the immune system by bacteria. Treatment options for IgA heavy chain disease include chemotherapy and antibiotics with or without corticosteroids.